Additional file 9 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

Additional file 9: Supplementary Table 40. OS analysis of patients with CESC. Supplementary Table 41. Kaplan Meier analysis of the correlation between IGLC1 gene expression and OS of patients with CESC. Supplementary Table 42. Kaplan Meier analysis of the correlation between IGLC2 gene expression and OS of patients with CESC. Supplementary Table 43. Kaplan Meier analysis of the correlation between IGLC3 gene expression and OS of patients with CESC. Supplementary Table 44. Kaplan Meier analysis of the correlation between IGLC6 gene expression and OS of patients with CESC. Supplementary Table 45. Kaplan Meier analysis of the correlation between IGLC7 gene expression and OS of patients with CESC. Supplementary Table 46. DSS analysis of patients with CESC. Supplementary Table 47. Kaplan Meier analysis of the correlation between IGLC1 gene expression and Dss of patients with CESC. Supplementary Table 48. Kaplan Meier analysis of the correlation between IGLC2 gene expression and Dss of patients with CESC. Supplementary Table 49. Kaplan Meier analysis of the correlation between IGLC3 gene expression and Dss of patients with CESC. Supplementary Table 50. Kaplan Meier analysis of the correlation between IGLC6 gene expression and Dss of patients with CESC. Supplementary Table 51. Kaplan Meier analysis of the correlation between IGLC7 gene expression and Dss of patients with CESC. Supplementary Table 52. DFI analysis of patients with CESC. Supplementary Table 53. Kaplan Meier analysis of the correlation between IGLC1 gene expression and DFI of patients with CESC. Supplementary Table 54. Kaplan Meier analysis of the correlation between IGLC2 gene expression and DFI of patients with CESC. Supplementary Table 55. Kaplan Meier analysis of the correlation between IGLC3 gene expression and DFI of patients with CESC. Supplementary Table 56. Kaplan Meier analysis of the correlation between IGLC6 gene expression and DFI of patients with CESC. Supplementary Table 57. Kaplan Meier analysis of the correlation between IGLC7 gene expression and DFI of patients with CESC. Supplementary Table 58. PFI analysis of patients with CESC. Supplementary Table 59. Kaplan Meier analysis of the correlation between IGLC1 gene expression and PFI of patients with CESC. Supplementary Table 60. Kaplan Meier analysis of the correlation between IGLC2 gene expression and PFI of patients with CESC. Supplementary Table 61. Kaplan Meier analysis of the correlation between IGLC3 gene expression and PFI of patients with CESC. Supplementary Table 62. Kaplan Meier analysis of the correlation between IGLC6 gene expression and PFI of patients with CESC. Supplementary Table 63. Kaplan Meier analysis of the correlation between IGLC7 gene expression and PFI of patients with CESC.